Efficacy of Asacol

Maintenance of Remission

In a 6-Month Study, Asacol Delivered Maintenance of Remission in 70% of Patients

According to the ACG Guidelines, maintaining remission is a key goal of ulcerative colitis therapy.1

Improvement in Symptoms and Muscosal Healing in Proctitis Patients

References: 1. Kornbluth A et al. Am J Gastroenterol. 2004;99:1371-1385. 2. The Mesalamine Study Group. Ann Intern Med. 1996;124:204-211. 3. Asacol Package Insert. October 2007. Procter & Gamble Pharmaceuticals, Inc. Cincinnati, OH.

Asacol Delivers Divided Dosing for the Maintenance of Remission of Ulcerative Colitis

According to the ACG Guidelines, maintaining remission is a key goal of UC therapy.1

Patients in Remission
  • FDA-approved maintenance dosage is 1.6 g/day in divided doses

References: 1. Kornbluth A et al. Am J Gastroenterol. 2004;99:1371-1385. 2. Data on file, Procter & Gamble Pharmaceuticals, Inc.

Asacol (mesalamine) delayed-release tablets, available only by prescription, are indicated to treat mild to moderate flare-ups of ulcerative colitis and maintain remission of ulcerative colitis. Asacol is generally well-tolerated. In studies of flare-ups, some people taking Asacol reported headache, abdominal pain, general pain, rash, upset stomach, and worsening of colitis symptoms. In a six-month maintenance study, some people reported headache, runny nose, general pain, sore throat, infection, and nervousness. You should not take Asacol if you are allergic to Asacol or to salicylates such as aspirin. Tell your doctor if you have kidney problems or a history of kidney disease. It is recommended that all people have their kidney function tested prior to starting Asacol tablets and periodically while on Asacol therapy. Serious side effects may occur. If you have questions about taking Asacol, please talk to your doctor.
Adjust Font SizeSmall TextMedium TextLarge Text

This information was printed from Asacol.com.
Visit Asacol.com to get more information on Ulcerative Colitis.
Asacol is a registered trademark of Medeva Pharma Suisse AG, used under license by Procter & Gamble Pharmaceuticals, Inc.

Privacy BBB OnLine